<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405636</url>
  </required_header>
  <id_info>
    <org_study_id>XEL-CR-02</org_study_id>
    <nct_id>NCT03405636</nct_id>
  </id_info>
  <brief_title>Xeltis Pulmonary Valved Conduit Safety and Performance Study</brief_title>
  <official_title>Prospective, Non-randomized, Open Label Clinical Study to Assess the Safety and Performance of the Xeltis Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeltis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xeltis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center prospective, single-arm, non-randomized, open label study to assess&#xD;
      safety and performance of the Xeltis Pulmonary Valved Conduit in subjects requiring Right&#xD;
      Ventricular Outflow Tract correction or reconstruction due to congenital heart malformations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study not started&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at 12 months follow up post implantation</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by the fact that the patient is still alive at the time of the 12 month FU visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from device related death, intervention and/or reoperation at 12 months follow up</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by the fact that the patient did not die, did not have a reoperation or reintervention during the first 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pressure gradient across the area of conduit implantation (RV to PA) of less than 40 mm Hg at 12 months follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary regurgitation of equal or less than moderate (≤40 %) at 12 months follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Defects, Congenital</condition>
  <arm_group>
    <arm_group_label>Xeltis Pulmonary Valved Conduit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PV Conduit for RVOT reconstruction</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xeltis Pulmonary Valved Conduit</intervention_name>
    <description>RVOT reconstruction</description>
    <arm_group_label>Xeltis Pulmonary Valved Conduit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient requiring RVOT reconstruction, suitable for 16 mm or 18 mm valved conduit.&#xD;
&#xD;
          2. Male or Female.&#xD;
&#xD;
          3. Age &lt; 22 years.&#xD;
&#xD;
          4. Right Ventricular to Pulmonary Artery mean gradient &gt; 35mm Hg or moderate or severe&#xD;
             Pulmonary regurgitation (≥3+), or have both.&#xD;
&#xD;
          5. The patient, and the patient's parent / legal representative where appropriate, has&#xD;
             been informed of the nature of the study, agrees to its provisions and has provided&#xD;
             written informed consent by signing the approved informed consent form.&#xD;
&#xD;
          6. The patient, and the patient's parent / legal representative where appropriate, and&#xD;
             the treating physician agree that the subject will return for all required&#xD;
             post-procedure follow up visits and the subject will comply with clinical&#xD;
             investigation plan required follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Need for or presence of prosthetic heart valve at other position&#xD;
&#xD;
          2. Need for concomitant surgical procedures (non-cardiac)&#xD;
&#xD;
          3. Patients with previously implanted pacemaker (including defibrillators) or mechanical&#xD;
             valves&#xD;
&#xD;
          4. Active bacterial or viral infection or requiring current antibiotic therapy (if&#xD;
             temporary illness, patient may be a candidate 4 weeks after discontinuation of&#xD;
             antibiotics)&#xD;
&#xD;
          5. Active endocarditis&#xD;
&#xD;
          6. Leukopenia, according to local laboratory evaluation of white blood cell count&#xD;
&#xD;
          7. Acute or chronic anemia, according to local laboratory evaluation of hemoglobin&#xD;
             Patients can be transfused to meet eligibility criteria&#xD;
&#xD;
          8. Thrombocytopenia, defined as Platelet count &lt; 150,000/mm3 Patients can be transfused&#xD;
             to meet eligibility criteria&#xD;
&#xD;
          9. Severe chest wall deformity, which would preclude placement of the PV conduit&#xD;
&#xD;
         10. Pulmonary hypertension (right ventricular systolic pressure ≥ half of systemic&#xD;
             systolic pressure)&#xD;
&#xD;
         11. Right ventricular outflow tract aneurysm&#xD;
&#xD;
         12. Known hypersensitivity to anticoagulants and antiplatelet drugs and to the device&#xD;
             materials&#xD;
&#xD;
         13. Immunocompromised patient defined as: autoimmune disease, patients receiving&#xD;
             immunosuppressant drugs or immune stimulant drugs&#xD;
&#xD;
         14. Patient has chronic inflammatory / autoimmune disease&#xD;
&#xD;
         15. Need for emergency cardiac or vascular surgery or intervention&#xD;
&#xD;
         16. Major or progressive non-cardiac disease (liver failure, renal failure, cancer) that&#xD;
             has a life expectancy of less than one year&#xD;
&#xD;
         17. Currently participating, or participated within the last 30 days, in an&#xD;
             investigational drug or device study&#xD;
&#xD;
         18. Alcohol or drug abuse as defined by DSM IV-TR criteria for substance abuse - this&#xD;
             includes the illicit use of cannabis within the last 12 months&#xD;
&#xD;
         19. Females who are sexually active and are not willing to use adequate contraceptive&#xD;
             precautions for the next 2 years&#xD;
&#xD;
         20. Patient has medical, social or psychosocial factors that, in the opinion of the&#xD;
             Investigator, could have impact on safety or compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gottsegen György Hungarian Institute of Cardiology, Paediatric Cardiac Centre</name>
      <address>
        <city>Budapest</city>
        <zip>H-1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Jantung Negara, National Heart Institute</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital of Cracow (UCH),</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Heart Centre Slovak Republic</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

